Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key De... (llion in revenueover the next three to f...)

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

Date:11/6/2008

llion in revenue over the next three to four years.

2008 FINANCIAL GUIDANCE

HGS updated the financial guidance provided in late February 2008:

-- HGS expects 2008 net cash burn of $245 million to $265 million. -- Revenue is expected to increase from $42 million in 2007 to a range of $45-50 million in 2008.

-- HGS expects cash and investments at year-end 2008 to total $350 million to $370 million, compared with approximately $604 million at the end of 2007.

HGS is confident that it will receive $150 million in 2009 for delivery of 20,000 doses of ABthrax to the U.S. Strategic National Stockpile, with an additional $15 million expected upon FDA licensure.

CONFERENCE CALL

HGS management will hold a conference call to discuss this announcement today at 5 PM Eastern. Investors may listen to the call by dialing 866-550- 6338 or 347-284-6930, passcode 6760480, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203- 1112 or 719-457-0820, confirmation code 6760480. Today's conference call also will be webcast and can be accessed at http://www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins to download any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.

ABOUT HUMAN GENOME SCIENCES

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
2. Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
3. Complete Genomics Chooses Isilon IQ to Power Worlds First Complete Human Genome Sequencing Service
4. Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
5. Human Pheromone Sciences, Inc. - Shareholder Update
6. The human brain minimizes energy expenditure and integrates gravity in to the action plan
7. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
8. Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs
9. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
10. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference

Post Your Comments:

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key De...(llion in revenueover the next three to f...)